Mini-Brain Platform Mimics Human Brain to Help Develop Drugs, Test Therapies

Studying the effect of potential therapies on the human brain is exceedingly difficult. Laboratory animals have proven to be less than ideal as mimics for identifying how a given therapy will work in people, leading to exceedingly long and difficult research journeys.

Now AxoSim, a company based in New Orleans, will soon be making its Mini-Brain platform available to researchers who are studying how the brain functions, developing new drugs, and testing the toxicity of various chemicals. The technology behind the Mini-Brain has been licensed from Johns Hopkins University, where it was originally developed.

The Mini-Brain platform is a technique that provides the ability to create functional models of the human brain using induced pluripotent stem cells (iPSCs). As the iPSCs have been induced to grow into human brain-like cells, which then form the building blocks of these models, research studies employing the platform should be a lot more accurate, reproducible, and faster.

“Acquiring rights to the intellectual property underlying the Mini-Brain technology is a major step forward in our drive to transform neurology drug research,” said Lowry Curley, PhD, Chief Executive Officer of AxoSim. “Mini-Brains are live organoids that mimic multiple brain functions, allowing for a wide variety of applications in neurotoxicity and neurological diseases with the potential to substantially speed-up and increase the effectiveness of new drug R&D. The Mini-Brain technology complements our innovative Nerve-on-a-Chip platform and accelerates our strategy of providing the broadest and most scientifically robust neuroscience models to our growing roster of biopharmaceutical partners.”

Here’s a short video from AxoSim introducing its Mini-Brain platform:

Link: Mini-Brain technology info page…

Via: AxoSim